A proportion of patients who undergo total neoadjuvant therapy for rectal cancer will achieve what is classified as a near-complete response. Significant debate exists as to the optimal management strategy for these patients with large heterogeneity in management. This article will examine the therapeutic and surveillance options for these patients as well as the relevant outcomes data.
Keyphrases
- rectal cancer
- locally advanced
- end stage renal disease
- public health
- lymph node
- ejection fraction
- newly diagnosed
- chronic kidney disease
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- metabolic syndrome
- electronic health record
- radiation therapy
- stem cells
- mesenchymal stem cells
- cell therapy
- deep learning